Title: Risk of diabetes and cardiovascular diseases in women with vaginal bleeding before 20 gestational weeks: Danish population-based cohort study

Elena Dudukina, Erzsébet Horváth-Puhó, Henrik Toft Sørensen, Vera Ehrenstein

¹Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark

Corresponding author:

Elena Dudukina

Olof Palmes Alle 43-45

8200

Aarhus N

Email: e.dudukina@clin.au.dk

Word count: 3420

Abstract word count: 347

ABSTRACT (347/350 MAX)

Importance: The risk of cardiovascular outcomes following a pregnancy complicated by vaginal bleeding (VB) not ending in a miscarriage is not well investigated.

Objective: To study an association between pregnancy affected by VB and women's subsequent risks of metabolic and cardiovascular outcomes.

Design, Setting and Participants: This was a population-based cohort study set in Denmark, 1994-2018. Using Danish nationwide registries, we identified 1,901,725 pregnancies among 903,327 women. Of these, 39,265 were affected by VB and ended in childbirth; 1,389,285 were unaffected by VB and ended in childbirth; 333,785 ended in termination, and 139,390 ended in a miscarriage.

Exposure(s): Pregnancy affected by vaginal bleeding before 20 gestational weeks.

Main outcome measures: The outcomes were diabetes types 1 and 2, hypertension, ischaemic heart disease (including myocardial infarction), atrial fibrillation or flutter, heart failure, ischaemic and haemorrhagic stroke. We computed absolute risks and hazard ratios (aHRs) with robust 95% confidence intervals (CIs) adjusted for age, calendar year, reproductive history, comorbidities, and socioeconomic factors using Cox proportional hazards regression.

Results: At the end of the follow-up, among women with VB-affected vs VB-unaffected pregnancies, the cumulative risks of the outcome events were 1.7% vs 1.4% for diabetes type 1; 6.9% vs 5.6% for diabetes type 2; 11.1% vs 9.0% for hypertension; 3.6% vs 2.7% for ischaemic heart disease, including 1.1% vs 0.8% for myocardial infarction; 1.3% vs 1.0% for atrial fibrillation or flutter; 0.5% vs 0.5% for heart failure; 2.0% vs 1.3% for ischaemic stroke; and 0.8% vs 0.6% for haemorrhagic stroke and aHRs were 1.2 to 1.3-fold increased for diabetes types 1 and 2, hypertension, ischaemic heart disease, myocardial infarction, atrial fibrillation or flutter, and heart failure. The aHRs were 1.4 and 1.5-fold increased for ischaemic and haemorrhagic stroke, respectively. For comparisons of women with VB-affected pregnancy vs termination, aHRs were up to 1.3-fold increased for diabetes and hypertension. Analyses contrasting VB-affected pregnancy with miscarriage resulted in aHRs below or close to the null value.

Conclusions: Women's risks of metabolic and cardiovascular outcomes were increased following VB-affected pregnancy when compared with VB-unaffected pregnancy or termination, but not when compared with miscarriage.

Key points

Question: Is having a pregnancy affected by vaginal bleeding and not ending in miscarriage associated with the increased risk of metabolic and cardiovascular outcomes in women?

Findings: This nationwide registry-based cohort study of 1,901,725 pregnancies among 903,327 women showed that in contrast with having a pregnancy without vaginal bleeding, having a pregnancy with vaginal bleeding before 20 gestational weeks was associated with woman's increased risks of diabetes types 1 and 2, hypertension, ischaemic heart disease, including myocardial infarction, atrial fibrillation or flutter, heart failure, ischaemic and haemorrhagic stroke. The cardiovascular risks were increased when investigating a woman's first pregnancy with vaginal bleeding before 20 gestational vs without vaginal bleeding during pregnancy; the associations remained when we additionally adjusted for smoking and body-mass index in a sensitivity analysis. The long-term cardiovascular risk of women having a vaginal bleeding-affected pregnancy was similar to that of women having a miscarriage.

Meaning: The results of this study do not promote changes in clinical practice; however, they add to the body of evidence on a common pregnancy complication and the associated long-term risks of metabolic and cardiovascular conditions.

INTRODUCTION

Women's reproductive health is a predictor of cardiovascular morbidity.¹ First pregnancy ending in a miscarriage is associated with a 20% greater relative risk of hypertension and type 2 diabetes,^{2,3} whereas more than one miscarriage is associated with a 10-20% increased risk of stroke, thromboembolism, ischaemic heart disease, and 30% increased risk of cardiovascular diseases.^{1,4,5}

Vaginal bleeding (VB) affects up to 30%^{6–8} of clinically recognised pregnancies a third of pregnancies complicated by VB ends in a pregnancy loss. ^{9,10} At the same time, there are little data on whether VB not followed by a pregnancy loss is associated with subsequent cardiovascular morbidity. An earlier Danish study¹¹ reported a 25-60% higher risk of multiple cardiovascular outcomes in women following a pregnancy with VB in the first trimester without subsequent miscarriage vs unaffected pregnancy; however, analyses did not control for pre-pregnancy conditions or socioeconomic factors. Comparisons of VB-affected pregnancies with pregnancies ending in terminations or miscarriages are missing in the literature.

We investigated the association of VB before 20 gestational weeks of a pregnancy ending in a childbirth with the woman's subsequent risks of diabetes, hypertension, ischaemic heart disease, including myocardial infarction, atrial fibrillation or flutter, heart failure, and ischaemic and haemorrhagic stroke.

METHODS

Setting and design

We conducted a registry-based cohort study using prospectively and routinely recorded data of the Danish nationwide registries, ^{12,13} which are collected in the context of Denmark's universal tax-supported healthcare. Data from all registries are linkable via a unique personal identifier stored in the Civil Registration System (CRS). ¹² It captures the civil and vital status of all residents, country of origin, immigration, and emigration dates. Data on all deliveries are stored in the Medical Birth Registry (MBR) available from 1973. ¹⁴ Smoking and body mass index (BMI) in pregnancy became available in the MBR starting in 1991 and 2004, respectively. Hospital encounters and procedures are captured by the Danish National Patient Registry (DNPR). ¹⁵ It stores data on medical procedures, inpatient hospital encounters since 1977 and also on outpatient specialist clinic visits and emergency room visits starting in 1995. ¹⁵ The diagnoses recorded in the DNPR are coded according to the International Classification of Diseases, 8th revision (ICD-18) in 1977-1993 and 10th revision (ICD-10) from 1994 onwards, while procedures are coded using the Danish Classification of Surgical Procedures and Therapies before 1996 and

Nordic Medico-Statistical Committee Classification of Surgical Procedures afterwards. The psychiatric admissions and outpatient specialist clinic encounters were available for this study starting from 1995 from the Psychiatric Central Research Register. Nationwide data on medication prescriptions were available starting in 1995 from the Danish National Prescription Registry. This registry captures the Anatomical Therapeutic Classification code of the prescribed medication, and the date prescription was redeemed. Data on education, employment and income are available from 1980, measured yearly and stored at Statistics Denmark.

Study population

From the MBR, we assembled a cohort of women whose pregnancies ended in a live or stillbirth. Each delivery of multi-foetal pregnancy was counted as one pregnancy (Figure 1). From the DNPR, we ascertained two cohorts of women whose pregnancies ended in a termination or miscarriage.

We excluded records of women with any pre-existing outcome of interest, venous thrombotic event, records of women with two or more prescriptions for antihypertensives from different classes redeemed within 180 days of each other before the index date as a proxy for hypertension as well as records of women with pre-existing hypercholesterolaemia, hyperlipidaemia or arterial claudication, prescription for clopidogrel or statins before the index date (altogether 2.3% of all eligible observations). We further excluded records with missing gestational age (2.1% of all eligible observations) and records with delivery, miscarriage, termination, or VB recorded on the same date (0.2% of all eligible observations). Finally, we excluded records of women whose personal identifier could not be linked with the CRS data, records with potentially wrongly registered women's age (<12 years) at the time of hospital-based encounter for delivery, miscarriage, termination, or VB (0.2% of all eligible observations); and pregnancies recorded after a woman emigrated from Denmark (0.1% of all eligible observations) (Figure 1). We also ascertained the subset of women having their first pregnancy recorded as either delivery, miscarriage or termination.

Exposed cohort

Among women having a pregnancy ending in a childbirth, we identified pregnancies affected by VB before 20 gestational weeks, using the DNPR. When several VB episodes occurred before 20 gestational weeks of the same pregnancy, the first episode served as the qualifying event (Figure 1). The index date was the date of delivery when all cohort-specific eligibility criteria were met.

The comparison cohorts

The women whose pregnancies ended in a delivery and had no record of VB before the 20th gestational week in the DNPR formed a comparison cohort of women with VB-unaffected pregnancy and the index date was the date of delivery.

We ascertained women having a pregnancy ending in a termination or miscarriage using the primary and secondary diagnoses at any hospital visit. When a miscarriage or pregnancy termination encounter had several dates associated with it (hospital admission, procedure, hospital discharge), we selected the earliest of them as the index date (Table 1 in the Supplementary materials). A woman with a pregnancy termination encounter characterised by the same diagnostic or procedure code as her previous encounter could re-enter the population with another pregnancy after 180 days. We assumed that the hospital encounter with the same pregnancy-related diagnostic or procedure code within 180 days since an earlier such encounter may be related to the complications of the previous event. We applied the same algorithm for women with pregnancies ending in miscarriage.

Outcomes

The outcomes were incident diabetes type 1 and type 2, hypertension, ischaemic heart disease, including myocardial infarction, atrial fibrillation or flutter, heart failure, ischaemic and haemorrhagic stroke. We used all available primary and secondary diagnoses recorded in connection with inpatient, outpatient specialist clinic, and emergency room encounters from the DNPR (1994-2018). Diabetes and hypertension outcomes were defined based on the earliest of the hospital-based diagnosis or medication dispensing (Table 1 in the Supplementary materials). In a sensitivity analysis covering the period from 1979 through 2018 and allowing a longer follow-up, we included two additional long-term cardiovascular outcomes (coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)). These outcomes were defined using procedure codes from the DNPR (Table 1 in the Supplementary materials).

Covariables

Potential confounding factors were selected using the directed acyclic graph presenting the evidence on the associations or lack thereof between the measured and unmeasured variables in this study (Figure 1 in the Supplementary materials). These were women's age, calendar year of pregnancy end, parity (nulli- or primiparous vs multiparous) as the number of delivered live and stillborn infants, preindex date number of identifiable pregnancies ending in delivery, termination or miscarriage, civil status, employment status, highest attained education, annual women's income in quartiles; reproductive history (VB diagnosis irrespective of a later delivery, history of VB before 20th gestational week of pregnancy ending in a childbirth, histories of at least one termination or miscarriage, history of preeclampsia-eclampsia, placenta praevia, abruptio placentae, gestational diabetes), obesity, chronic obstructive pulmonary disease (COPD), chronic kidney and liver diseases, cancer, and psychiatric conditions before the index date. As a proxy for the

underlying long-term health, we also ascertained the medication use (antipsychotics, mood disorders medication, antiepileptics, non-steroid anti-inflammatory drugs [NSAIDs], steroids for systemic use, anti-infectives) history before the end of 12th gestational week for pregnancies ending in a childbirth and before the index date for pregnancies ending in termination or miscarriage.

Statistical analysis

We followed each observation of a woman from its index date until the earliest of each of the outcomes, emigration, death, or end of data on 31 December 2018. We constructed the cumulative incidence curves for the outcomes while treating death and emigration as competing risks and computed incidence rates (IR) of the outcomes per 10,000 person-years (PY) for women having VB-affected and VB-unaffected pregnancy, termination, or miscarriage. We used Cox proportional hazards regression to compute the adjusted hazards ratios (HRs) for the outcomes of interest with the corresponding 95% confidence intervals (CIs) adjusted for age, calendar year, reproductive history, comorbidities, and socioeconomic factors. Different outcomes did not censor one another. In analyses of all identifiable pregnancies, we did not censor an observation at the time the next pregnancy occurred to avoid informative censoring. Different pregnancies of the same woman could contribute person-time to multiple cohorts. To account for different pregnancies in the same woman, we computed the 95% CIs using a robust standard error estimation with *survival* or *Weightlt* R packages. 23-26

Contrasting women with VB-affected pregnancy with each of the comparators, we computed the inverse probability of treatment weighted (IPTW) models for an average treatment effect, where treatment refers to VB exposure (Figure 1 in the Supplementary materials). ^{26–28} We truncated large IPT weights (>50) at the 99th percentile. ^{26,28} The covariables balance after IPT weighting was evaluated using standardized mean difference (SMD). Finally, we repeated all analyses restricting to a woman's first identifiable pregnancy. Additionally, we computed conventionally adjusted HRs using multivariable Cox proportional hazards regression models. We evaluated the proportionality of hazards assumptions by using log-minus-log plots and found no deviation of the curves from being parallel for all Cox proportional hazards regression models.

We performed several sensitivity analyses. First, we conducted analyses of women with identifiable pregnancies in the ICD-8 era from 1979 through 1993 and investigated the risks of two additional outcomes (CABG and PCI). Second, we restricted analyses to women with pregnancies from 2004 through 2017 while further adjusting analyses of VB-affected vs VB-unaffected pregnancies for pre-pregnancy BMI. For the contrasts of VB-affected vs VB-unaffected pregnancy, we computed E-

values quantifying the strength of the unmeasured confounding needed to explain the findings.

For all analyses, we used RStudio²⁹ and R³⁰ versions 3.6.0-4.1.0 including the following packages and their dependencies: tidyverse,³¹ ggplot2,^{32(p2)} survival,²⁴ cmprsk,³³ epiR,³⁴ and WeightIt (Weighting for Covariate Balance in Observational Studies).²⁶ All presented counts were masked to comply with the rules of Statistics Denmark.²¹ We did not impute missing values for covariables since the missingness was relatively rare.

No patient informed consent or ethical approval is required for registry-based research according to Danish legislation. The study was reported to the Danish Data Protection Agency³⁵ through registration at Aarhus University (record number: AU-2016-051-000001, sequential number 605).

RESULTS

Descriptive characteristics

Between 1994 and 2017, we identified 1,901,725 pregnancy records among 903,327 women. Of ascertained pregnancies, 1,428,550 ended in a delivery (39,265 [2.1%] were VB-affected before 20th week of gestation and 1,389,285 [73.1%] were VBunaffected pregnancies); 333,785 (17.6%) ended in a termination, and 139,390 (7.2%) pregnancies ended in a miscarriage. Women having VB-affected and VB-unaffected pregnancies had a similar distribution of age at delivery, parity, civil status, employment, highest attained education, yearly income, history of COPD, obesity, polycystic ovary syndrome (PCOS), chronic kidney and liver disease, alcohol abuse, and medication use (Table 1). Women having VB-affected pregnancies were more likely than women having VB-unaffected pregnancies to have a prior miscarriage (23.0% vs 12.0%), prior VB-affected pregnancy (6.3% vs 2.1%) and a prior psychiatric condition (13.0% vs 9.8%). For deliveries at investigation, VB-affected vs VBunaffected pregnancies were more often complicated by abruption placentae (1.1% vs 0.5%) and placenta praevia (1.3% vs 0.5%). Women having a termination were more likely to be younger, nulliparous, not married, in the first income guartile and with a prior psychiatric condition (Table 1). The median follow-up (25-75th percentile) was 13.3 (7.2-19.2) years and differed slightly by the outcome at the investigation.

Risks and rates of the outcomes

Following VB-affected pregnancy there were 365 events of diabetes type 1 (IR=6.1, 95% CI: 5.5-6.8 per 10,000 PY); 1,425 events of diabetes type 2 (24.4, 95% CI: 23.1-25.6); 2,120 events of hypertension (36.5, 95% CI: 34.9-38.0); 720 events of ischaemic heart disease (12.2, 95% CI: 11.4-13.1), including 180 events of myocardial infarction (3.0, 95% CI: 2.6-3.5); 235 events of atrial fibrillation or flutter (4.0, 95% CI: 3.5-4.5);

100 events of heart failure (1.7, 95% CI: 1.4-2.0); 390 ischaemic stroke events (6.6, 95% CI: 5.9-7.2) and 165 haemorrhagic stroke events (2.8, 95% CI: 2.4-3.3) (Table 2).

At the end of follow-up, for women with VB-affected vs VB-unaffected pregnancies, the cumulative incidences of the outcomes were: 1.7% vs 1.4% for diabetes type 1; 6.9% vs 5.6% for diabetes type 2; 11.1% vs 9.0% for hypertension; 3.6% vs 2.7% for ischaemic heart disease, including 1.1% vs 0.8% for myocardial infarction; 1.3% vs 1.0% for atrial fibrillation or flutter; 0.5% vs 0.5% for heart failure; 2.0% vs 1.3% for ischaemic stroke; and 0.8% vs 0.6% for haemorrhagic stroke (Figure 2 in the Supplementary materials). The cumulative incidences of the outcomes at 5, 10, 20, and 25 years of follow-up are reported in Table 2 in the Supplementary materials.

Hazard ratios

After IPT weighting and trimming, all covariables were balanced within SMD cut-off of 0.05 for women with VB-affected vs VB-unaffected pregnancy and vs miscarriage and within SMD cut-off of 0.15 for women with VB-affected pregnancy vs pregnancy ending in a termination.

Women with VB-affected vs VB-unaffected pregnancy, were at a greater risk of diabetes type 1 (IPTW-adjusted HR [IPTW aHR]: 1.15, 95% CI: 1.03-1.28), diabetes type 2 (IPTW aHR: 1.19, 1.13-1.26), hypertension (IPTW aHR: 1.19, 1.14-1.25), ischaemic heart disease (IPTW aHR: 1.26, 1.16-1.37) and specifically myocardial infarction (IPTW aHR: 1.21, 1.03-1.42), atrial fibrillation or flutter (IPTW aHR: 1.32, 1.14-1.51), heart failure (IPTW aHR: 1.23, 0.99-1.52), ischaemic (IPTW aHR: 1.41, 1.26-1.57) and haemorrhagic stroke (IPTW aHR: 1.46, 1.23-1.72). The elevated risks persisted in the analyses following a woman's first pregnancy (Table 2). The conventionally adjusted HRs were similar in magnitude for all outcomes but heart failure (conventionally aHR: 1.08, 0.88-1.32; Table 3 in the Supplementary materials). When comparing women with VB-affected pregnancy vs having a termination, the risks were increased for diabetes type 1 (IPTW aHR: 1.29, 95% CI: 1.11-1.49), diabetes type 2 (IPTW aHR: 1.33, 1.23-1.43), hypertension (IPTW aHR: 1.35, 1.26-1.43), ischaemic heart disease (IPTW aHR: 1.20, 1.07-1.33), atrial fibrillation or flutter (IPTW aHR: 1.12, 0.93-1.36), ischaemic stroke (IPTW aHR: 1.14, 0.98-1.32). Associations with myocardial infarction (IPTW aHR: 1.12, 0.90-1.39) and heart failure (IPTW aHR: 1.12, 0.85-1.49) were compatible with the null value and showed estimates close to unity in conventionally adjusted analyses. In analyses of a woman's first pregnancy, the associations remained 1.2 to 1.4-fold increased for diabetes types 1 and 2, hypertension, ischaemic heart disease, and ischaemic and haemorrhagic stroke (Table

When contrasted with having a miscarriage, having a VB-affected pregnancy was not associated with hypertension, ischaemic heart disease, including myocardial infarction, atrial fibrillation or flutter, heart failure, ischaemic, and haemorrhagic

stroke in women. However, IPTW aHRs for diabetes types 1 and 2 suggested reduced risks of these outcomes (Table 3).

The risks remained increased for all outcomes after additional adjustment for women's BMI in the comparisons of VB-affected vs VB-unaffected pregnancy and when investigated in the study period 1979-1993. In these analyses, for the contrast of VB-affected pregnancy vs VB-unaffected pregnancy, the IPTW aHR were 1.28 (95% CI: 0.98-1.68) and 1.20 (95% CI: 1.06-1.35) for CABG and PCI, respectively (Table 4 and Table 5 in the Supplementary materials).

DISCUSSION

Principal findings

In this population-based cohort study, the hazards of diabetes types 1 and 2 as well as of cardiovascular outcomes were 1.2 to 1.5-fold increased for women with VB-affected vs VB-unaffected pregnancies. The associations persisted in the analyses restricted to first identifiable pregnancies and in the sensitivity analyses additionally controlling for BMI and allowing for a longer follow-up. We found that the hazards of diabetes types 1 and 2, hypertension, ischaemic heart disease, atrial fibrillation or flutter, and haemorrhagic stroke were 1.2 to 1.3-fold greater for women having a VB-affected pregnancy vs termination. No increased risks of the outcomes of interest were observed in the comparisons of women having a VB-affected pregnancy vs miscarriage. The findings suggest that having a pregnancy complicated by VB was associated with increased cardiovascular risk.

Biological mechanisms

Underlying biological mechanisms of VB in pregnancy are not fully known. Markers of systemic inflammation are associated with both miscarriages 36,37 and VB in pregnancy $^{38-41}$ and were found to contribute to the development of cardiovascular disease and diabetes type $2.^{42}$ Dyslipidaemia, insulin resistance, and obesity are risk factors for diabetes type 2 and hypertension, which result in endothelial dysfunction and microvascular inflammation and damage further leading to cardiovascular diseases. 43 The existence of common metabolic and pro-inflammatory pathways via cytokines (IL-1 β , IL-6, TNF- α) for VB, miscarriage and vascular pathology could contribute to the explanation of the findings of this study showing an elevated cardiovascular risk in women with a VB-affected pregnancy vs women having a VB-unaffected pregnancy or a termination but not a miscarriage.

Comparison with other studies

An earlier Danish study showed a greater risk of cardiovascular morbidity following pregnancies with VB. 11 This study differed from the earlier study in several ways. First,

we used a different definition of VB and aligned it with the clinical definition of threatened miscarriage, more years of follow-up were available for this study and investigated outcomes included specific stroke and diabetes types. Second, we carried out comparisons with pregnancies ending in a termination or miscarriage. Third, analyses in this study were adjusted for socioeconomic factors and prepregnancy morbidity. We did not adjust for post-exposure factors such as preterm delivery, prelabour rupture of membranes, foetal growth restriction, placental abruption and stillbirth. These could be both mediators and colliders on the pathway from VB in pregnancy to subsequent cardiovascular morbidity in women. Adjusting for post-exposure factors that are colliders could result in inflated associations. 44 VB is known to be associated with obstetric complications such as abruptio placentae and placenta praevia. 45 We adjusted analyses for preeclampsia-eclampsia, abruptio placentae, and placenta praevia at the index pregnancy, assuming these were not mediators but proxies of the underlying vascular condition potentially also leading to VB, which manifested post-exposure. Results of analyses additionally adjusted vs unadjusted for placental complications did not differ appreciably.

Strengths and limitations of the study

The strengths of this study are population-based design, up to 25 years of available follow-up in the main analysis, use of validated diagnostic codes for the outcomes and nearly complete follow-up of women until emigration, death, or the outcome of interest, which minimizes the selection bias.

The VB diagnosis was not validated in the DNPR. However, one Danish study showed that most women with VB in pregnancy received ultrasound required to establish foetal heart activity at bleeding presentation and exclude miscarriage and ectopic pregnancy. The number of false-positive VBs in this study is likely small. At the same time, we were unable to capture episodes of VB not resulting in a hospital-based contact and, therefore, could miss a considerable proportion of pregnancies affected by milder bleeding. Non-differential misclassification of pregnancies' status would result in diluted associations. The diagnoses for miscarriage (spontaneous abortion) in the DNPR were previously validated and showed PPV of 97%. The diagnostic and procedure codes for medical and surgical abortions (pregnancy terminations) were not validated in the DNPR, however, the induced abortion diagnosis in the Register of Legally Induced Abortions had PPV of 94% and procedure codes, in general, have high validity in the DNPR.

The outcome diagnoses were validated with high PPV for diabetes (82-96%), ⁴⁷ hypertension (92%), PCI (98%), ⁴⁸ and slightly lower PPV for heart failure (76%), ⁴⁸ and haemorrhagic stroke (71-80%). ^{49,50} The PPV for ischaemic stroke was 71-85%; ^{49,50} however, since the definition of ischaemic stroke in this study included undefined stroke diagnoses, a larger proportion of false positives may be present. Non-

differential misclassification of the outcome is expected to dilute the associations toward or beyond the null value.

The residual confounding by obesity is likely since data only on hospital-based diagnoses were available. Although additional adjustment of analyses for BMI did not meaningfully shift the aHR estimates, the concern of unmeasured and residual confounding remains. The prevalence of PCOS was similar across all cohorts in this study, however, we had no data on other indicators of low-grade inflammation in women. An unmeasured confounder associated with VB and with cardiovascular outcomes with the hazard ratio of 1.6-2.2 beyond measured covariables could fully explain away the observed associations according to the E-value analysis (Table 5 in the Supplementary materials).⁵¹

Although we did not investigate the specific pathways of cardiovascular morbidity in women following a VB-affected pregnancy, associations with diabetes type 2 and hypertension suggest that metabolic syndrome may be one of them. We cannot exclude that part of the observed association between VB and the outcomes may be mediated via miscarriages of women's subsequent pregnancies.

CONCLUSION

Having a pregnancy affected by VB before 20 gestational weeks was associated with an increased relative risk of diabetes types 1 and 2 and multiple cardiovascular outcomes in women when compared with having a VB-unaffected pregnancy or termination, but not miscarriage. An unmeasured confounder associated with VB and with cardiovascular outcomes with a hazard ratio of 1.6-2.2 beyond measured covariables could explain the findings.

Contributors: ED, EHP, HTS, VE designed the study. HTS facilitated the data application process. ED designed the statistical analysis plan. ED conducted the analyses, EHP provided expertise and supervision of the data analysis. All authors participated in the discussion of the results and their critical interpretation. ED drafted the manuscript, organised the writing, and produced a graphical presentation of the results. HTS provided clinical expertise. All authors equally participated in the critical revision of the manuscript and approved its final version. HTS is the quarantor.

Funding: Department of Clinical Epidemiology, Aarhus University partaking in studies with institutional funding from regulators and pharmaceutical companies, given as research grants to and administered by Aarhus University. None of these projects is related to the current study.

Competing interests: All authors report no competing interest

Ethics approval: not required for registry-based research in Denmark.

Data sharing: data is not available for sharing to protect the identity of participants according to Danish legislation.

REFERENCES

- 1. Okoth K, Chandan JS, Marshall T, et al. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. *BMJ*. 2020;371:m3502. doi:10.1136/bmj.m3502
- 2. Horn J, Tanz LJ, Stuart JJ, et al. Early or late pregnancy loss and development of clinical cardiovascular disease risk factors: a prospective cohort study. *BJOG: An International Journal of Obstetrics & Gynaecology.* 2019;126(1):33-42. doi:10.1111/1471-0528.15452
- 3. Harvey RE, Coffman KE, Miller VM. Women-specific factors to consider in risk, diagnosis and treatment of cardiovascular disease. *Womens Health (Lond Engl)*. 2015;11(2):239-257. doi:10.2217/whe.14.64
- 4. Quenby S, Gallos ID, Dhillon-Smith RK, et al. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. *The Lancet*. 2021;397(10285):1658-1667. doi:10.1016/S0140-6736(21)00682-6
- 5. Oliver-Williams CT, Heydon EE, Smith GC, Wood AM. Miscarriage and future maternal cardiovascular disease: a systematic review and meta-analysis. *Heart*. 2013;99(22):1636-1644. doi:10.1136/heartinl-2012-303237
- Axelsen SM, Henriksen TB, Hedegaard M, Secher NJ. Characteristics of vaginal bleeding during pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology. 1995;63(2):131-134. doi:10.1016/0301-2115(95)02236-8
- 7. Smits LJM, North RA, Kenny LC, Myers J, Dekker GA, Mccowan LME. Patterns of vaginal bleeding during the first 20 weeks of pregnancy and risk of pre-eclampsia in nulliparous women: results from the SCOPE study. *Acta Obstetricia et Gynecologica Scandinavica*. 2012;91(11):1331-1338. doi:10.1111/j.1600-0412.2012.01496.x
- 8. Saraswat L, Bhattacharya S, Maheshwari A, Bhattacharya S. Maternal and perinatal outcome in women with threatened miscarriage in the first trimester: a systematic review. *BJOG*. 2010;117(3):245-257. doi:10.1111/j.1471-0528.2009.02427.x
- 9. Coomarasamy A, Harb HM, Devall AJ, et al. Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT. *Health Technol Assess*. 2020;24(33):1-70. doi:10.3310/hta24330
- 10. Coomarasamy A, Gallos ID, Papadopoulou A, et al. Sporadic miscarriage: evidence to provide effective care. *The Lancet*. 2021;397(10285):1668-1674. doi:10.1016/S0140-6736(21)00683-8
- 11. Lykke JA, Langhoff-Roos J. First trimester bleeding and maternal cardiovascular morbidity. *Eur J Obstet Gynecol Reprod Biol.* 2012;164(2):138-141. doi:10.1016/j.ejogrb.2012.06.003

- 12. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. *Eur J Epidemiol*. 2014;29(8):541-549. doi:10.1007/s10654-014-9930-3
- 13. Laugesen K, Ludvigsson JF, Schmidt M, et al. Nordic Health Registry-Based Research: A Review of Health Care Systems and Key Registries. *CLEP*. 2021;13:533-554. doi:10.2147/CLEP.S314959
- 14. Bliddal M, Broe A, Pottegard A, Olsen J, Langhoff-Roos J. The Danish Medical Birth Register. *Eur J Epidemiol.* 2018;33(1):27-36. doi:10.1007/s10654-018-0356-1
- 15. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol.* 2015;7:449-490. doi:10.2147/CLEP.S91125
- 16. Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. *Scand J Public Health*. 2011;39(7 Suppl):54-57. doi:10.1177/1403494810395825
- 17. Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M. Data Resource Profile: The Danish National Prescription Registry. *Int J Epidemiol*. 2017;46(3):798-798f. doi:10.1093/ije/dyw213
- 18. Jensen VM, Rasmussen AW. Danish Education Registers. *Scand J Public Health*. 2011;39(7 Suppl):91-94. doi:10.1177/1403494810394715
- 19. Petersson F, Baadsgaard M, Thygesen LC. Danish registers on personal labour market affiliation. *Scand J Public Health*. 2011;39(7_suppl):95-98. doi:10.1177/1403494811408483
- 20. Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. *Scand J Public Health*. 2011;39(7 Suppl):103-105. doi:10.1177/1403494811405098
- 21. Statistics Denmark. Published 2021. Accessed June 30, 2021. https://www.dst.dk/en
- 22. Austin PC, Lee DS, Fine JP. Introduction to the Analysis of Survival Data in the Presence of Competing Risks. *Circulation*. 2016;133(6):601-609. doi:10.1161/CIRCULATIONAHA.115.017719
- 23. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000. Springer; 2000.
- 24. Therneau TM, Thomas L, Elizabeth A, Cynthia C. survival: Survival Analysis. Published online March 16, 2021. Accessed April 6, 2021. https://CRAN.R-project.org/package=survival
- 25. Efron B. Nonparametric Estimates of Standard Error: The Jackknife, the Bootstrap and Other Methods. *Biometrika*. 1981;68(3):589-599. doi:10.2307/2335441

- 26. Using WeightIt to Estimate Balancing Weights. Accessed February 17, 2022. https://ngreifer.github.io/WeightIt/articles/WeightIt.html
- 27. Hernán M, Robins JM. *Causal Inference*.; 2021. Accessed July 29, 2021. https://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/#:~:text=To%20cite%20the%20book%2C%20please,Chapman%20%26%20Hall%2 FCRC.%E2%80%9D
- 28. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. *Am J Epidemiol*. 2008;168(6):656-664. doi:10.1093/aje/kwn164
- RStudio Team. RStudio: Integrated Development for R. Published online 2020. http://www.rstudio.com/
- 30. R Core Team. R: A language and environment for statistical computing. Published online 2013. http://www.R-project.org/
- 31. Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. *Journal of Open Source Software*. 2019;4(43):1686. doi:10.21105/joss.01686
- 32. Wickham H. *Ggplot2: Elegant Graphics for Data Analysis:Elegant Graphics for Data Analysis*. Springer-Verlag New York; 2016. https://ggplot2.tidyverse.org
- 33. Gray B. cmprsk: Subdistribution Analysis of Competing Risks. Published online June 9, 2020. Accessed March 31, 2021. https://CRAN.R-project.org/package=cmprsk
- 34. Nunes MS and ES with contributions from T, Heuer C, Marshall J, et al. epiR: Tools for the Analysis of Epidemiological Data. Published online July 19, 2021. Accessed July 29, 2021. https://CRAN.R-project.org/package=epiR
- 35. Datatilsynet. Datatilsynet/The Danish Data Protection Agency. Datatilsynet/The Danish Data Protection Agency. Accessed September 16, 2020. http://www.datatilsynet.dk/english
- 36. Ahmed SK, Mahmood N, Malalla ZH, Alsobyani FM, Al-Kiyumi IS, Almawi WY. C-reactive protein gene variants associated with recurrent pregnancy loss independent of CRP serum levels: A case-control study. *Gene.* 2015;569(1):136-140. doi:10.1016/j.gene.2015.05.052
- 37. Calleja-Agius J, Jauniaux E, Pizzey AR, Muttukrishna S. Investigation of systemic inflammatory response in first trimester pregnancy failure. *Human Reproduction*. 2012;27(2):349-357. doi:10.1093/humrep/der402
- 38. Calleja-Agius J, Schembri-Wismayer P, Calleja N, Brincat M, Spiteri D. Obstetric outcome and cytokine levels in threatened miscarriage. *Gynecol Endocrinol.* 2011;27(2):121-127. doi:10.3109/09513590.2010.487614

- 39. Calleja-Agius J, Muttukrishna S, Pizzey AR, Jauniaux E. Pro- and antiinflammatory cytokines in threatened miscarriages. *American Journal of Obstetrics and Gynecology*. 2011;205(1):83.e8-16. doi:10.1016/j.ajog.2011.02.051
- 40. Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Llurba E, Gris JM. Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. *Clin Rev Allergy Immunol*. 2017;53(1):40-53. doi:10.1007/s12016-016-8596-x
- 41. Gücer F, Balkanli-Kaplan P, Yüksel M, Sayin NC, Yüce MA, Yardim T. Maternal serum levels of tumor necrosis factor-α and interleukin-2 receptor in threatened abortion: a comparison with normal and pathologic pregnancies. *Fertility and Sterility*. 2001;76(4):707-711. doi:10.1016/S0015-0282(01)02002-7
- 42. Willerson JT, Ridker PM. Inflammation as a Cardiovascular Risk Factor. *Circulation*. 2004;109(21_suppl_1):II-2. doi:10.1161/01.CIR.0000129535.04194.38
- 43. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. *Can J Cardiol*. 2018;34(5):575-584. doi:10.1016/j.cjca.2017.12.005
- 44. Hernandez-Diaz S, Schisterman EF, Hernan MA. The birth weight "paradox" uncovered? Am J Epidemiol. 2006;164(11):1115-1120. doi:10.1093/aje/kwj275
- 45. Wijesiriwardana A, Bhattacharya S, Shetty A, Smith N, Bhattacharya S. Obstetric Outcome in Women With Threatened Miscarriage in the First Trimester. *Obstetrics & Gynecology*. 2006;107(3):557-562. doi:10.1097/01.AOG.0000199952.82151.de
- 46. Lohse SR, Farkas DK, Lohse N, et al. Validation of spontaneous abortion diagnoses in the Danish National Registry of Patients. *Clin Epidemiol*. 2010;2:247-250. doi:10.2147/CLEP.S13815
- 47. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. *BMC Med Res Methodol*. 2011;11:83. doi:10.1186/1471-2288-11-83
- 48. Sundbøll J, Adelborg K, Munch T, et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. *BMJ Open.* 2016;6(11):e012832. doi:10.1136/bmjopen-2016-012832
- 49. Lühdorf P, Overvad K, Schmidt EB, Johnsen SP, Bach FW. Predictive value of stroke discharge diagnoses in the Danish National Patient Register. *Scand J Public Health*. 2017;45(6):630-636. doi:10.1177/1403494817716582

- 50. Wildenschild C, Mehnert F, Thomsen RW, et al. Registration of acute stroke: validity in the Danish Stroke Registry and the Danish National Registry of Patients. *Clin Epidemiol*. 2013;6:27-36. doi:10.2147/CLEP.S50449
- 51. Mathur MB, Ding P, Riddell CA, VanderWeele TJ. Web Site and R Package for Computing E-values. *Epidemiology*. 2018;29(5):e45. doi:10.1097/EDE.0000000000000864

Figure 1. Flow graph depicting ascertainment of the study population Standalone file

Table 1. Descriptive characteristics of women having vaginal bleeding-affected and vaginal bleeding-unaffected pregnancy, pregnancy ending in termination or in miscarriage, Denmark, 1994-2017

	Cohorts				
1994-1999 2000-2003 2004-2008 2009-2012 2013-2017 Age at the pregnancy et <20 20-24 25-29 30-34 35-39	VB-affected pregnancy	VB-unaffected pregnancy	Termination	Miscarriage	
No. of observations	39,265	1,389,290	333,785	139,390	
-	37,587	797,086	246,039	123,482	
Characteristics	n (%)	n (%)	n (%)	n (%)	
Calendar year at the preg	inancy end			_	
1994-1999	11,745 (30.0)	310,065 (22.0)	87,745 (26.0)	33,705 (24.0)	
2000-2003	11,405 (29.0)	300,475 (22.0)	79,105 (24.0)	31,370 (23.0)	
2004-2008	5,790 (15.0)	236,610 (17.0)	56,970 (17.0)	25,540 (18.0)	
2009-2012	5,910 (15.0)	277,065 (20.0)	62,620 (19.0)	31,015 (22.0)	
2013-2017	4,420 (11.0)	265,070 (19.0)	47,340 (14.0)	17,760 (13.0)	
Age at the pregnancy end	d, years				
<20	635 (1.6)	21,260 (1.5)	48,190 (14.0)	4,820 (3.5)	
20-24	5,475 (14.0)	171,915 (12.0)	77,510 (23.0)	18,245 (13.0)	
25-29	13,135 (33.0)	479,420 (35.0)	70,745 (21.0)	38,835 (28.0)	
30-34	13,015 (33.0)	480,550 (35.0)	66,955 (20.0)	40,255 (29.0)	
35-39	5,885 (15.0)	200,830 (14.0)	49,725 (15.0)	25,945 (19.0)	
40+	1,115 (2.8)	35,315 (2.5)	20,665 (6.2)	11,290 (8.1)	
Parity at the pregnancy e	nd				
Nulliparous	0 (0.0)	0 (0.0)	213,450 (64.0)	113,105 (81.0)	
Primiparous	18,065 (46.0)	642,235 (46.0)	33,135 (9.9)	10,695 (7.7)	
Multiparous	21,200 (54.0)	747,050 (54.0)	87,200 (26.0)	15,590 (11.0)	
Number of pregnancies b	efore the index dat	e			
1	11,845 (30.0)	522,685 (38.0)	117,465 (35.0)	44,985 (32.0)	
2	12,170 (31.0)	456,045 (33.0)	61,825 (19.0)	40,865 (29.0)	
3	7,565 (19.0)	237,480 (17.0)	60,295 (18.0)	25,875 (19.0)	
3+	7,680 (20.0)	173,075 (12.0)	94,200 (28.0)	27,665 (20.0)	
Civil status					
Married or in	23,390 (60.0)	042 245 (61.0)	105 265 (22.0)	60 475 (50 0)	
partnership	25,390 (60.0)	842,345 (61.0)	105,265 (32.0)	69,475 (50.0)	
Not married	11,740 (30.0)	407,025 (29.0)	168,380 (50.0)	43,805 (31.0)	
Missing	4,135 (11.0)	139,915 (10.0)	60,140 (18.0)	26,110 (19.0)	
Employment status					
Employed	28,480 (73.0)	1,033,855 (74.0)	200,235 (60.0)	100,220 (72.0)	
Retirement or state pension	3,645 (9.3)	104,425 (7.5)	42,890 (13.0)	13,310 (9.5)	
Unemployed	6,160 (16.0)	207,605 (15.0)	83,260 (25.0)	21,845 (16.0)	
Missing	980 (2.5)	43,400 (3.1)	7,400 (2.2)	4,010 (2.9)	
Highest achieved educati		43,400 (S.I)	1,400 (Z.Z)	4,010 (2.3)	
Basic education	10,655 (27.0)	282,630 (20.0)	150,535 (45.0)	36,685 (26.0)	

	Cohorts				
	VB-affected pregnancy	VB-unaffected pregnancy	Termination	Miscarriage	
No. of observations	39,265	1,389,290	333,785	139,390	
No. of unique women	37,587	797,086	246,039	123,482	
Characteristics	n (%)	n (%)	n (%)	n (%)	
High school or similar	16,020 (41.0)	567,950 (41.0)	112,395 (34.0)	54,530 (39.0)	
Higher education	10,925 (28.0)	472,585 (34.0)	49,905 (15.0)	41,160 (30.0)	
Missing	1,665 (4.2)	66,120 (4.8)	20,945 (6.3)	7,010 (5.0)	
Yearly income, quartiles					
Q1	9,475 (24.0)	288,055 (21.0)	135,505 (41.0)	33,765 (24.0)	
Q2	9,950 (25.0)	332,420 (24.0)	83,470 (25.0)	34,805 (25.0)	
Q3	9,395 (24.0)	364,780 (26.0)	53,750 (16.0)	33,335 (24.0)	
Q4	9,740 (25.0)	368,815 (27.0)	48,825 (15.0)	33,795 (24.0)	
missing	705 (1.8)	35,210 (2.5)	12,230 (3.7)	3,685 (2.6)	
Origin					
Danish	33,020 (84.0)	1,182,850 (85.0)	282,390 (85.0)	117,215 (84.0)	
Non-Danish	6,240 (16.0)	205,995 (15.0)	51,395 (15.0)	22,175 (16.0)	
Missing	5 (<0.1)	445 (<0.1)	0 (0.0)	0 (0.0)	
Vaginal bleeding	, ,	, ,	, ,	,	
history irrespective of	5,135 (13.0)	66,505 (4.8)	24,005 (7.2)	17,145 (12.0)	
pregnancy end	. ,	, ,	, ,	, , ,	
Previous vaginal					
bleeding within 20 gw					
of a pregnancy ending	2,480 (6.3)	29,680 (2.1)	12,140 (3.6)	5,080 (3.6)	
in delivery					
History of at least one					
termination	9,200 (23.0)	230,020 (17.0)	112,300 (34.0)	30,735 (22.0)	
History of at least one					
miscarriage	8,915 (23.0)	169,975 (12.0)	39,240 (12.0)	21,135 (15.0)	
History of any					
preeclampsia-	1,325 (3.4)	42,050 (3.0)	10,200 (3.1)	5,095 (3.7)	
eclampsia	_,=_= (=: .,	, (5.5)		5,000 (017)	
History of placenta					
praevia	95 (0.2)	3,405 (0.2)	1,020 (0.3)	470 (0.3)	
History of abruptio					
placentae	260 (0.7)	5,985 (0.4)	2,075 (0.6)	925 (0.7)	
History of gestational					
diabetes	210 (0.5)	8,120 (0.6)	1,815 (0.5)	1,090 (0.8)	
Any preeclampsia-					
eclampsia or other					
hypertensive disorders	1,610 (4.1)	49,420 (3.6)	-	-	
at the index pregnancy					
Abruptio placentae at					
the index pregnancy	425 (1.1)	7,355 (0.5)	-	-	
Placenta praevia at the					
index pregnancy	500 (1.3)	7,340 (0.5)	-	-	
Gestational diabetes at					
the index pregnancy	690 (1.8)	22,025 (1.6)	-	-	
Gestation age at	39.0 (38.0,	40.00 (39.0,			
delivery of the index	40.0)	40.00 (59.0, 41.0)	-	-	
delivery of the index	40.0)	41.0)			

	Cohorts					
	VB-affected pregnancy	VB-unaffected pregnancy	Termination	Miscarriage 139,390 123,482		
No. of observations	39,265	1,389,290	333,785			
No. of unique women	37,587	797,086	246,039			
Characteristics	n (%)	n (%)	n (%)	n (%)		
pregnancy, median (25-75 percentile) weeks						
Obesity diagnosis	2,190 (5.6)	93,205 (6.7)	10,240 (3.1)	5,235 (3.8)		
PCOS Thyroid disorders Rheumatic disorders COPD	225 (0.6) 890 (2.3) 20 (<0.1) 465 (1.2)	6,970 (0.5) 28,645 (2.1) 580 (<0.1) 14,060 (1.0)	755 (0.2) 4,900 (1.5) 135 (<0.1) 3,485 (1.0)	680 (0.5) 2,755 (2.0) 60 (<0.1) 1,465 (1.1)		
Chronic kidney diseases	90 (0.2)	2,300 (0.2)	645 (0.2)	255 (0.2)		
Chronic liver diseases Cancer Schizophrenia	95 (0.2) 205 (0.5) 330 (0.8)	3,145 (0.2) 7,615 (0.5) 8,370 (0.6)	910 (0.3) 1,755 (0.5) 5,615 (1.7)	340 (0.2) 790 (0.6) 1,295 (0.9)		
Autism spectrum disorders	25 (<0.1)	805 (<0.1)	530 (0.2)	100 (<0.1)		
Neurotic disorders Eating disorders Personality disorder Intellectual disability Behavioural disorder Alcohol abuse history	3,600 (9.2) 465 (1.2) 1,285 (3.3) 30 (<0.1) 45 (0.1) 395 (1.0)	89,340 (6.4) 13,315 (1.0) 30,195 (2.2) 775 (<0.1) 1,230 (<0.1) 9,505 (0.7)	42,230 (13.0) 5,570 (1.7) 18,850 (5.6) 630 (0.2) 940 (0.3) 10,230 (3.1)	11,610 (8.3) 1,570 (1.1) 4,565 (3.3) 115 (<0.1) 185 (0.1) 1,955 (1.4)		
History of any psychiatric condition	5,030 (13.0)	135,865 (9.8)	60,995 (18.0)	17,065 (12.0)		
Smoking status recorded	•					
Smoker Non-smoker	7,915 (20.0) 27,375 (70.0)	222,360 (16.0) 1,061,620 (76.0)	-	=		
Missing	27,373 (70.0) 3,970 (10.0)	1,061,620 (76.0)	-	-		

Table 2. Incidence rates following vaginal bleeding-affected and vaginal bleeding-unaffected pregnancy, pregnancy ending in termination or in miscarriage, Denmark, 1994-2017

		No. of events				Incidence rate, 1	0,000 PY (95% CI)		
Outcome Pregnancy observations	Pregnancy	VB-affected	VB-unaffected	Termination	Miscarriage	VB-affected	VB-unaffected	Termination	Miscarriage
	observations	pregnancy	pregnancy			pregnancy	pregnancy		
Diabetes mellitus	All observations ^a	365	8, 835	2,605	1,475	6.1 (5.5-6.8)	4.9 (4.8-5.0)	5.6 (5.4-5.8)	7.7 (7.3-8.1)
type 1	First observations b	100	3,075	730	435	5.9 (4.8-7.1)	4.7 (4.6-4.9)	4.7 (4.3-5.0)	7.8 (7.1-8.6)
Diabetes mellitus	All observations ^a	1,425	32,835	9,245	5,140	24.4 (23.1-25.6)	18.2 (18.0-18.4)	20.0 (19.6-20.4)	27.2 (26.4-27.9)
type 2	First observations b	405	11,495	2,700	1,585	24.7 (22.3-27.1)	17.9 (17.5-18.2)	17.3 (16.7-18.0)	29.0 (27.6-30.4)
Hypertension	All observations ^a	2,120	49,855	12,590	6,375	36.5 (34.9-38.0)	27.9 (27.6-28.1)	27.4 (26.9-27.9)	33.8 (33.0-34.7)
	First observations b	690	20,530	3,560	2,055	42.7 (39.6-46.0)	32.2 (31.8-32.7)	23.0 (22.3-23.8)	37.7 (36.1-39.3)
Ischemic heart	All observations ^a	720	14,405	5,140	2,190	12.2 (11.4-13.1)	7.9 (7.8-8.1)	11.1 (10.8-11.4)	11.4 (11.0-11.9)
disease	First observations b	120	3,485	785	370	7.3 (6.1-8.7)	5.4 (5.2-5.5)	5.0 (4.6-5.3)	6.6 (6.0-7.4)
Myocardial	All observations ^a	180	3,735	1,360	560	3.0 (2.6-3.5)	2.0 (2.0-2.1)	2.9 (2.8-3.1)	2.9 (2.7-3.1)
infarction	First observations b	35	835	200	80	2.0 (1.4-2.8)	1.3 (1.2-1.4)	1.3 (1.1-1.5)	1.5 (1.2-1.8)
Atrial fibrillation	All observations ^a	235	4, 935	1,470	675	4.0 (3.5-4.5)	2.7 (2.6-2.8)	3.1 (3.0-3.3)	3.5 (3.2-3.8)
or flutter	First observations b	60	1,370	270	155	3.5 (2.7-4.5)	2.1 (2.0-2.2)	1.7 (1.5-1.9)	2.8 (2.4-3.2)
Heart failure	All observations ^a	100	2, 255	820	330	1.7 (1.4-2.0)	1.2 (1.2-1.3)	1.8 (1.6-1.9)	1.7 (1.5-1.9)
	First observations b	20	63 0	150	55	1.1 (0.7-1.7)	1.0 (0.9-1.0)	0.9 (0.8-1.1)	0.9 (0.7-1.2)
Ischemic stroke	All observations ^a	390	7,115	2,630	1,060	6.6 (5.9-7.2)	3.9 (3.8-4.0)	5.6 (5.4-5.8)	5.5 (5.2-5.8)
	First observations b	65	1,900	470	210	4.0 (3.1-5.0)	2.9 (2.8-3.0)	3.0 (2.7-3.3)	3.8 (3.3-4.3)
Haemorrhagic	All observations ^a	165	3,215	1,235	445	2.8 (2.4-3.3)	1.8 (1.7-1.8)	2.6 (2.5-2.8)	2.3 (2.1-2.5)
st ro ke	First observations b	40	945	255	95	2.3 (1.7-3.2)	1.4 (1.4-1.5)	1.6 (1.4-1.8)	1.7 (1.4-2.1)

^a Different pregnancies of the same woman were allowed.

^b We followed the first pregnancy of each woman. The cohort membership was classified according to the exposure status at the first pregnancy identifiable via the registries. VB; vaginal bleeding

Table 3. Adjusted hazard ratios with 95% confidence intervals for the associations between vaginal bleeding before 20 weeks of gestation and cardiovascular outcomes, Denmark, 1994-2018

Pregnancy observations VB-affected pregnancy vs **Outcomes** observations a, b observations Comparator VB-unaffected pregnancy^d Diabetes mellitus type 1 1.15 (1.03-1.28) 1.11 (0.98-1.26) Termination 1.29 (1.11-1.49) 1.25 (1.07-1.45) Miscarriage 0.81 (0.69-0.95) 0.85 (0.74-0.98) VB-unaffected pregnancy^d Diabetes mellitus type 2 1.30 (1.22-1.39) 1.19 (1.13-1.26) Termination 1.33 (1.23-1.43) 1.37 (1.27-1.49) Miscarriage 0.86 (0.80-0.94) 0.98 (0.91-1.06) VB-unaffected pregnancy^d Hypertension 1.19 (1.14-1.25) 1.16 (1.11-1.21) Termination 1.35 (1.26-1.43) 1.16 (1.10-1.22) Miscarriage 1.09 (1.02-1.17) 0.99 (0.94-1.04) Ischemic heart disease VB-unaffected pregnancy^d 1.26 (1.16-1.37) 1.37 (1.26-1.49) Termination 1.20 (1.07-1.33) 1.19 (1.08-1.32) Miscarriage 0.96 (0.86-1.09) 1.07 (0.97-1.17) Myocardial infarction VB-unaffected pregnancy 1.21 (1.03-1.42) 1.24 (1.05-1.47) Termination 1.12 (0.90-1.39) 1.03 (0.84-1.26) Miscarriage 0.85 (0.67-1.09) 0.96 (0.80-1.16) Atrial fibrillation or VB-unaffected pregnancy^d 1.32 (1.14-1.51) 1.26 (1.10-1.45) flutter Termination 1.12 (0.93-1.36) 0.86 (0.72-1.02) 1.01 (0.83-1.23) 0.85 (0.73-0.99) Miscarriage VB-unaffected pregnancy^d Heart failure 1.23 (0.99-1.52) 1.15 (0.94-1.42) Termination 1.12 (0.85-1.49) 0.83 (0.65-1.06) Miscarriage 0.89 (0.65-1.20) 0.83 (0.66-1.05) **Ischemic stroke** VB-unaffected pregnancy^d 1.41 (1.26-1.57) 1.30 (1.15-1.47) Termination 1.14 (0.98-1.32) 1.07 (0.92-1.25) Miscarriage 0.93 (0.79-1.10) 1.02 (0.89-1.17) VB-unaffected pregnancy Hemorrhagic stroke 1.46 (1.23-1.72) 1.34 (1.12-1.61) Termination 1.10 (0.87-1.38) 1.18 (0.94-1.48) Miscarriage 0.96 (0.75-1.23) 1.12 (0.91-1.38)

^a Adjusted using IPT-weighted Cox proportional hazards regression for women's age at pregnancy end, calendar year, parity, the number of previous pregnancies ending in childbirth, termination or miscarriage identifiable via registries, civil status, employment, highest attained education, income in year-specific quartiles, reproductive history (histories of at least one previous vaginal bleeding, termination, miscarriage, preeclampsia-eclampsia, placenta praevia, abruption placentae), comorbidities (obesity, chronic pulmonary disease, chronic kidney disease, chronic liver disease, thyroid, cancer, rheumatic conditions, thyroid conditions, alcohol abuse), history of any psychiatric condition, and medication use (antipsychotics, antiepileptics, medication for mood disorders, NSAIDs or aspirin, thyroid disorders medication, steroids for systemic use, anti-infectives for systemic use).

^b Different pregnancies of the same women were allowed.

^c We followed the first pregnancy of each woman. The cohort membership was classified according to the exposure status at the first pregnancy identifiable via the registries.

^d Additionally adjusted for smoking status recorded at 1st prenatal visit, preeclampsia-eclampsia, placental praevia, and abruption placentae in the index pregnancy.

HR; hazard ratio

